This clinical trial focuses on treating patients with Multiple Myeloma, a type of blood cancer affecting plasma cells in the bone marrow. The study evaluates a treatment combination using elranatamab with lenalidomide and compares it to standard treatments. The medications used in the study include bortezomib, dexamethasone, daratumumab, and human normal immunoglobulin.
The purpose of this research is to determine if using elranatamab and lenalidomide together is more effective than current standard treatments for newly diagnosed multiple myeloma patients. The study is divided into two main phases: a consolidation phase, which follows initial treatment, and a maintenance phase, which aims to prevent the disease from returning.
During the study, patients will receive different combinations of medications through various methods, including oral capsules, tablets, and injections under the skin. Some medications will be given through an infusion into a vein. The treatment schedule will vary depending on which study group the patient is assigned to, and the total treatment period may last several months to years.
France 
